Current Report · Items 5.07, 9.01 · 8-K
Bio Green Med Solution, Inc. BGMS NASDAQ EQUITY Current
Add to THEMA watchlist → Follow this company’s filings → Submission of Matters to a Vote of Security Holders Item 9.01 Financial Statements and Exhibits. Exhibit Description No. ────────────────────────────────────────────────────────────────────────────────────── 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
Filed Nov 20, 2026 Accepted Nov 20, 2026, 4:15 PM EST CIK 1130166 Accession 0001493152-26-053492
Company context We are a clinical-stage biopharmaceutical company working to develop innovative cancer medicines based on cell cycle, epigenetics and mitosis biology. We are a pioneer company in the field of cancer cell cycle biology with a vision to improve patient healthcare by translating insights in cancer biology into medicines that can overcome resistance and ultimately increase a patient’s overall survival.
Current securities Historical securities (2) Registered securities in this filing Bio Green Med Solution, Inc. · 8-K · Filed 2026-11-20
As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.
Common Stock, par value $0.001 per share
Exchange NASDAQ
Classification COMMON
Status Current Filing context Context: AsOf2026-11-19
Dimensions: Not supplied
Accession 000149315226053492 · 1 registered-security cover member
Read the exact SEC filing ↗
Disclosure sections Items 5.07, 9.01 Select an item to read the extracted section. The as-filed document remains the primary evidence.
Item 9.01 Item 9.01 - Financial Statements and Exhibits Item
9.01 Financial Statements and Exhibits.
Exhibit Description
No.
──────────────────────────────────────────────────────────────────────────────────────
104 Cover
Page Interactive Data File (embedded within the Inline XBRL document)